An interventional study of Augmented reality app in Myocardial Infarction (MI), Pacemaker Implantation and Heart Failure, sponsored by Hospital Universitario Getafe. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.
Sponsored by Hospital Universitario Getafe · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 131 studies in Myocardial Infarction with a site in Spain — 19 open to participants now, 27 under way, 7 of them phase 3. Myocardial Infarction · Spain.
Among the 131 studies in Myocardial Infarction with a site in Spain, this one is the 59th largest by enrollment of the 98 interventional ones that give a count, is one of 5 that started in 2024, is one of 29 with no phase, and was the 127th registered.
2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.
Browse Myocardial Infarction studies →19 of the 131 studies in Myocardial Infarction with a site in Spain are open now. Recruiting first, the newest first:
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, Ireland, Latvia and 2 more countries
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Sergio Mies Padilla · Sites in Spain
Ages 18+
Novo Nordisk A/S · Sites in Spain, Austria, Denmark and 3 more countries
Ages 18+
Instituto de Investigación Biomédica de Salamanca · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
131 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 18 · Phase 3 35 · Phase 4 16
First in 2002; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 303 is above the median of 150 across 1,317 interventional studies indexed under Myocardial Infarction.
Median enrollment 445 across the 98 interventional studies, 1,498 across the 33 observational. Of the 91 that completed or were terminated, 29 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
51 of 131 have an industry lead sponsor. The 10 most frequent:
Hospital Universitario Getafe is the lead sponsor of 29 studies on the registry; 3 are open to participants now.
Hospital Universitario Getafe has 2 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
8 of the studies in Myocardial Infarction with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT06799780IRCCS Azienda Ospedaliero-Universitaria di BolognaStudy on Post-acute Myocardial Infarction Ventricular Defect: Outcome Evalutation in Relation to Surgical Timing | 2026-11-30 |
| NCT04973397Centre hospitalier de l'Université de Montréal (CHUM)Vascular Events In Patients Undergoing Same-day Noncardiac Surgery (VALIANCE) Study | 2026-12 |
| NCT07268391Instituto de Investigación Biomédica de SalamancaUsing Advanced CT Scans and Blood Markers to Better Understand Heart Damage and Recovery After a Heart Attack | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 131 studies in Myocardial Infarction with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to find out whether a simple augmented reality tool provided at hospital discharge can improve patients' understanding of their care, adherence to treatment, and health outcomes, compared with the usual discharge information.
This study includes adult patients who are admitted to a cardiology department because of:
The main questions this study aims to answer are:
Researchers will compare two groups of participants:
Participants will:
This is a low-intervention, randomized, single-centre clinical trial conducted in Getafe, Madrid, Spain. Participation in this study does not involve taking any additional medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
This group receives the usual medical discharge report plus an information card with a drawing and a QR code that gives access to an augmented reality application explaining their disease.
Device: Augmented reality app
This group receives the usual medical discharge report.
The card provided in addition to the usual medical discharge report is designed with a simple drawing that identifies each condition and a QR code. This code can be scanned from any mobile device using the device's camera. Once scanned, a 3D model of a heart or a stent (depending on the condition) appears on the device, showing movement, vibration, and sound as an example of augmented reality. The user can also access simple options through three buttons: 1. Video recorded by a cardiology professional: a brief and easy-to-understand explanation of the patient's condition, lasting approximately 2-3 minutes, provided by a hospital cardiology professional. 2. Treatment recommendations: a drop-down section with a table of discharge recommendations for the patient's condition, including lifestyle and dietary advice. 3. Warning signs: situations that the patient should pay attention to and seek medical advice if they occur.
PRIMARY OUTCOME: PREM and treatment adherence at one and six months
To assess PREM (Patient-Reported Experience Measures) in the intervention group and in the control group at discharge and at follow-up.
Time frame: Follow up at one and six months from enrollment
MACE at one and six months
Data on major adverse cardiovascular events (MACE) will also be collected at one and six months from discharge in both groups. MACE include heart attack, stroke, cardiovascular-related hospital readmission, and cardiovascular death.
Time frame: From enrollment at one and six months
Plan to share: No — Individual Participant Data will not be shared because the dataset contains sensitive patient health information, including medical history and follow-up outcomes. Sharing these data could risk patient confidentiality. All data will be handled according to current data protection regulations and only anonymized, aggregated results will be made publicly available.
Ran from Feb 2024 to primary completion in Dec 2025, 21 months.
Of 322 non-industry interventional studies with no phase under Myocardial Infarction, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's 21 months is below that.
Counting every sponsor, half of 355 studies reached it within 34 months; a quarter within 15 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitario Getafe